TRINETRA › Sectors › Healthcare
IOL Chemicals and Pharmaceuticals Limited (IOLCP) — share price, P/E and fundamentals
IOL Chemicals and Pharmaceuticals Limited (NSE: IOLCP) closed at ₹177.65 on 30 Oct 2026, +82.1% over one year, against a 52-week range of ₹67.19 – ₹224.00.
In the quarter ended 30 Sept 2026 (consolidated, filed 30 Oct 2026) it reported revenue of ₹795 cr and net profit of ₹65 cr, a 8.2% net margin; revenue grew 40.1% and profit grew 115.6% year on year.
On four consecutive filed quarters its trailing P/E is 25.7; since 19 May 2025 its own P/E has ranged from 17.3 to 38.4 (median 27.1), and today's reading is higher than 34% of those 359 trading days.
From the balance sheet dated 30 Sept 2026: return on equity 13.5%, ROCE 18.3%, debt-to-equity 0.10, Piotroski F-score 6 of 9.
Against 66 Healthcare peers on NSE: Net margin higher than 19% of 64 sector peers; PBT margin higher than 17% of 64 sector peers; ROE higher than 47% of 64 sector peers.
Key figures
| Last close | ₹177.65 (30 Oct 2026) |
|---|---|
| Change 1 month / 6 months / 1 year | -12.6% / +99.4% / +82.1% |
| 52-week low – high | ₹67.19 – ₹224.00 |
| Market capitalisation | ₹5,215 cr |
| Trailing P/E | 25.7 |
| Price / book | 2.71 |
| EV / EBITDA | 14.5 |
| Earnings yield | 3.9% |
| TTM EPS | ₹6.92 |
| TTM net profit | ₹203 cr |
| Quarter revenue | ₹795 cr |
| Quarter net profit | ₹65 cr |
| Net margin | 8.2% |
| Revenue growth (YoY) | +40.1% |
| Profit growth (YoY) | +115.6% |
| Return on equity | 13.5% |
| ROCE | 18.3% |
| Debt / equity | 0.10 |
| Current ratio | 1.70 |
| Free cash flow | ₹-133 cr |
| Piotroski F-score | 6 / 9 |
| Average daily turnover (50 days) | ₹59.8 cr |
Against Healthcare peers
| Metric | IOLCP | Peer median | Percentile |
|---|---|---|---|
| Net margin | 8.18 | 12.89 | 19 |
| PBT margin | 10.98 | 17.68 | 17 |
| ROE | 13.52 | 13.87 | 47 |
| ROCE | 18.28 | 17.26 | 59 |
| Debt / equity | 0.10 | 0.11 | 49 |
| FCF margin | -8.58 | -0.87 | 20 |
| Cash conversion | 0.06 | 1.25 | 5 |
| Trailing P/E | 25.66 | 43.26 | 13 |
Questions
What is the P/E ratio of IOL Chemicals and Pharmaceuticals Limited?
IOL Chemicals and Pharmaceuticals Limited's trailing P/E is 25.7, using the close of 30 Oct 2026 and earnings over the four filed quarters to 30 Sept 2026. Since 19 May 2025 its P/E has ranged 17.3–38.4.
What were IOL Chemicals and Pharmaceuticals Limited's latest quarterly results?
For the quarter ended 30 Sept 2026, IOL Chemicals and Pharmaceuticals Limited reported revenue of ₹795 cr and net profit of ₹65 cr (consolidated), filed with the exchange on 30 Oct 2026.
What is IOL Chemicals and Pharmaceuticals Limited's ROE?
Return on equity is 13.5% based on the balance sheet dated 30 Sept 2026.
Does IOL Chemicals and Pharmaceuticals Limited have debt?
Debt-to-equity is 0.10 on the balance sheet dated 30 Sept 2026.
What is IOLCP's 52-week high and low?
Over the last 52 weeks to 30 Oct 2026, IOLCP traded between ₹67.19 and ₹224.00.
Other Healthcare stocks
- Sun Pharmaceutical Industries Limited (SUNPHARMA)
- Divi's Laboratories Limited (DIVISLAB)
- Torrent Pharmaceuticals Limited (TORNTPHARM)
- Laurus Labs Limited (LAURUSLABS)
- Zydus Lifesciences Limited (ZYDUSLIFE)
- Apollo Hospitals Enterprise Limited (APOLLOHOSP)
- Dr. Reddy's Laboratories Limited (DRREDDY)
- Cipla Limited (CIPLA)
- Mankind Pharma Limited (MANKIND)
- Aurobindo Pharma Limited (AUROPHARMA)
- Lupin Limited (LUPIN)
- Max Healthcare Institute Limited (MAXHEALTH)
Source: consolidated SEBI Integrated Filing for the quarter ended 30 Sept 2026 and NSE daily closes. Open the interactive terminal view for charts and the full statements.
TRINETRA is a research and education tool. Nothing on this site is investment advice or a recommendation to buy or sell any security. Markets carry risk; do your own research and consult a SEBI-registered adviser before investing. Figures are as filed with NSE/SEBI and as of the dates shown; they are not live prices.